HEXO (TSX:HEXO) Is Now a Top Marijuana Stock

HEXO Corp’s (TSX:HEXO) stock has soared by 90% in 2019. Is the run over? Not likely. It has been a transformative week for the company.

| More on:
Hands holding trophy cup on sky background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The marijuana industry is in the midst of an impressive comeback. After crashing post-legalization, the Canadian Marijuana Index is now up 53% year to date. One company that has been making headlines for all the right reasons is HEXO (TSX:HEXO).

In 2019, the company has surged almost 90% and is among the big winners of the year. In the past week alone, the company’s share price has jumped almost 10%. Why? It has been a transformative week for the company.

Prior to releasing strong second-quarter results, the company announced a deal to acquire Newstrike Brands.

Why is the Newstrike Brands deal a good move?

Let’s start with the basics. HEXO has agreed to acquire Newstrike in an all-stock transaction. Newstrike shareholders will receive 0.06332 of a HEXO common share in exchange for each Newstrike share they hold. Although I am not a fan of these types of all-stock transactions, HEXO does not have a history of diluting shareholders on a regular basis.

One of the knocks against HEXO was that it was a regional play. Its distribution was largely dependent on the province of Quebec. Although it had distribution agreements in Ontario, it was not as diversified as some of the larger industry players. This all changed with the Newstrike deal.

The combined entity will have distribution agreements in eight provinces, significantly expanding the company’s market reach. It is also expected that the deal will enable HEXO the capacity to produce approximately 150,000 kg annually. This is a 38% increase from previous peak capacity production of 108,000 kg annually. This vaults it ahead of companies such as OrganiGram Holdings and Cronos Group.

As with any acquisition, there are expected synergies to be had. HEXO has pegged these synergies at approximately $10 million annually, which is considerable for a company of this size.

Strong second quarter

In the second quarter, HEXO grew revenues by 143% over the first quarter of 2018 and by 13.74 times the first quarter of 2017. This is explosive growth — better than the industry leaders. It is worth noting, however, that revenue missed analysts’ estimates by 4.41%. That’s not a big miss, but it marks the fifth consecutive quarter in which it missed expectations. The company also posted a $0.05-per-share loss, missing by a penny.

Adult use is the main growth driver for HEXO, with sales in the segment increasing by 200% over the previous quarter. Interestingly, revenue per gram sold increased by 7% from the first quarter of 2019. This bucked a recent trend in which revenue sold per gram in the industry was declining. Does this mean prices are stabilizing? As other companies report, investors will get a better idea. It was certainly an encouraging sign.

Foolish Takeaway

HEXO is starting to position itself as one of the top marijuana companies in the country. It has an oft-forgotten joint venture with Molson Coors and has taken a cautious approach to production expansion. The company is also cheap when compared to its peers. It has a forward price-to-sales ratio of 5.9 times 2020 revenue estimates. When compared to industry leader Canopy Growth, which is trading at 25 times 2020 sales, HEXO is cheap.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Mat Litalien has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »